Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cabozantinib before cytoreductive nephrectomy in advanced or metastatic renal cell carcinoma
2018-001201-93Phase 2Active
- Sponsor
- OncoSur
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by OncoSur. Primary endpoint: Objective response to preoperative treatment with cabozantinib. Started Aug 2018; status: active.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2018-001201-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001201-93.